Subgroups
Protocols (3)
Outcomes & scoring
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-intravenous-four-week-six-cycle | +35 | 85 | 614 |
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-intravenous-four-week-six-cycle | +45 | 85 | 614 |
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-abiraterone-acetate-combined | -30 | 70 | 403 |
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-intravenous-four-week-six-cycle | +40 | 85 | 614 |
| medication-cancer-prostate-radium-223-intravenous-generic | +50 | 85 | 614 |
qol-improvement-overall-perceived-rating-self-reported1 evidence row
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-intravenous-generic | +15 | 70 | 614 |
survival-fracture-occurrence-detected-binary-measured1 evidence row
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-abiraterone-acetate-combined | -40 | 70 | 403 |
survival-overall-proportion-cohort-measured1 evidence row
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-intravenous-generic | +60 | 85 | 614 |
survival-overall-time-months-measured1 evidence row
| Protocol | Effect | Confidence | N |
|---|---|---|---|
| medication-cancer-prostate-radium-223-intravenous-four-week-six-cycle | +35 | 85 | 614 |
Path: medication › cancer › prostate › radium